Sentences with phrase «chimpanzee adenovirus»
He's currently working on MHRP Ebola vaccine study RV429, a Phase II chimpanzee adenovirus type 3 Ebola vaccine study being conducted at MHRP's Nigeria site.
https://www.hivresearch.org/
2015 — Began a Phase 1b clinical trial of two experimental Ebola vaccines in Kampala, Uganda, using Chimpanzee Adenovirus type 3 vector (ChAd3) vaccines, co-developed by the VRC, National Institutes of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKine.
2015 — Began a new Ebola vaccine study in Abuja, Nigeria, using a monovalent chimpanzee adenovirus Type 3 (ChAd3) candidate developed at the NIAID and being developed by GlaxoSmithKline (GSK), the study sponsor.
Prime - boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adult.
Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
The vaccine that has been tested in the United States was made from a cold - causing chimpanzee adenovirus that had been engineered to express proteins from two species of the Ebola virus, known as Zaire and Sudan (after their origins), and that was already available when the trial began in early September.
The chimpanzee adenovirus is an alternative, says virologist Hildegund Ertl of the Wistar Institute in Philadelphia, Pennsylvania, and her colleagues.
Studies of sera from animal handlers and zoo workers exposed to chimpanzees in captivity fail to detect antibodies to chimpanzee adenoviruses [13], [14].
Not exact matches
Adenovirus 5 has 50 or so known relatives that infect humans and so in principle could also be used as a basis for vaccines, as could one from a chimpanzee.
The decreased levels of neutralizing Abs to TMAdV in the researcher (1 ∶ 32) and a family member (1 ∶ 8) relative to those in infected titi monkeys (up to > 1 ∶ 512) are consistent with a recent study showing much higher levels of neutralizing antibodies in chimpanzees than in humans with adenovirus infections, possibly due to more robust adenovirus - specific T - cell responses in humans than in monkeys [45].
To circumvent this problem, novel replication - defective adenoviral vaccine carriers based on El - deleted recombinants of chimpanzee - derived adenoviruses were developed.